Short answer
Orthofix Medical Inc. (OFIX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Management emphasizes adjusted EBITDA as its primary operating metric, alongside adjusted earnings, margins, expenses, and free cash flow.
Orthofix Medical Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Management emphasizes adjusted EBITDA as its primary operating metric, alongside adjusted earnings, margins, expenses, and free cash flow
- Exclusions include SeaSpine merger costs, M6 product-line losses, restructuring, litigation, acquisitions, and employee transitions
- M6 results are excluded because Orthofix exited those product lines, making reported GAAP results less representative of ongoing operations
- Long-term normalized tax rate assumption set at 28% for 2025 and 2026 adjusted results
- Extensive exclusions increase comparability but may omit recurring economic costs; investors should reconcile adjusted metrics with GAAP results
Item 7.01 · Regulation FD Disclosure
- Investor-relations presentation authorized for use through December 31, 2026
- Exhibit 99.2 may support presentations to investors, analysts, and other stakeholders
- Routine Reg FD disclosure; no new operating or financial information in the provided text
Item EX-99.1 · Exhibit EX-99.1
- Q2 net sales $210.9M, up 3.8% reported and 4.7% pro forma constant currency, supporting improved operating momentum
- Global Limb Reconstruction grew 13.2%, while Global Spine increased 3.5% pro forma, offsetting weaker portfolio areas
- Adjusted EBITDA $20.1M, down from $20.6M; margin declined to 9.6% from 10.3%, signaling limited near-term operating leverage
- Net loss widened to $15.8M from $14.1M, with cash flow pressured by $23.8M operating outflows and $47.1M free-cash-flow burn
- Full-year guidance raised to $845M–$855M sales and $95M–$98M adjusted EBITDA following Medicare reimbursement restoration
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Orthofix Medical Inc. 8-K filings
Get the next OFIX 8-K as it lands
Follow OFIX for push alerts, or ask the research agent what this filing means.